The University of Chicago Header Logo

Connection

James Vardiman to Myelodysplastic Syndromes

This is a "connection" page, showing publications James Vardiman has written about Myelodysplastic Syndromes.
Connection Strength

5.246
  1. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun. 2018 03 21; 9(1):1163.
    View in: PubMed
    Score: 0.479
  2. Acute Myeloid Leukemia With Myelodysplasia-Related Changes. Am J Clin Pathol. 2015 Jul; 144(1):29-43.
    View in: PubMed
    Score: 0.397
  3. Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome. Leukemia. 2013 Jun; 27(6):1291-300.
    View in: PubMed
    Score: 0.337
  4. The classification of MDS: from FAB to WHO and beyond. Leuk Res. 2012 Dec; 36(12):1453-8.
    View in: PubMed
    Score: 0.326
  5. Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol. 2011 Nov; 28(4):283-97.
    View in: PubMed
    Score: 0.308
  6. Acute myeloid leukemia with expanded erythropoiesis. Haematologica. 2011 Sep; 96(9):1241-3.
    View in: PubMed
    Score: 0.304
  7. Myelodysplastic syndromes. N Engl J Med. 2009 Nov 05; 361(19):1872-85.
    View in: PubMed
    Score: 0.268
  8. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010 Mar 19; 184(1-2):16-20.
    View in: PubMed
    Score: 0.268
  9. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5):937-51.
    View in: PubMed
    Score: 0.258
  10. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
    View in: PubMed
    Score: 0.222
  11. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006; 199-204.
    View in: PubMed
    Score: 0.205
  12. Myelodysplastic/myeloproliferative diseases. Cancer Treat Res. 2004; 121:13-43.
    View in: PubMed
    Score: 0.179
  13. Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. Semin Diagn Pathol. 2003 Aug; 20(3):154-79.
    View in: PubMed
    Score: 0.174
  14. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002 Oct 01; 100(7):2292-302.
    View in: PubMed
    Score: 0.164
  15. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood. 2002 Apr 15; 99(8):3074-5.
    View in: PubMed
    Score: 0.159
  16. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 05 19; 127(20):2391-405.
    View in: PubMed
    Score: 0.105
  17. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin Hematol. 1996 Apr; 33(2):111-26.
    View in: PubMed
    Score: 0.105
  18. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia. 1996 Jan; 10(1):20-6.
    View in: PubMed
    Score: 0.103
  19. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014 May; 99(5):821-9.
    View in: PubMed
    Score: 0.090
  20. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol. 1993 Apr; 99(4):513-25.
    View in: PubMed
    Score: 0.085
  21. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood. 1993 Mar 15; 81(6):1580-5.
    View in: PubMed
    Score: 0.085
  22. Issues in the pathology of the myelodysplastic syndromes. Hematol Oncol Clin North Am. 1992 Jun; 6(3):501-22.
    View in: PubMed
    Score: 0.080
  23. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009 Nov; 6(11):627-37.
    View in: PubMed
    Score: 0.067
  24. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009 Sep 01; 115(17):3842-7.
    View in: PubMed
    Score: 0.066
  25. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93.
    View in: PubMed
    Score: 0.063
  26. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood. 1988 Oct; 72(4):1333-9.
    View in: PubMed
    Score: 0.062
  27. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004; 297-317.
    View in: PubMed
    Score: 0.045
  28. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
    View in: PubMed
    Score: 0.042
  29. The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD. Clin Adv Hematol Oncol. 2003 Jan; 1(1):18, 21.
    View in: PubMed
    Score: 0.042
  30. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997 Nov; 99(2):344-51.
    View in: PubMed
    Score: 0.029
  31. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood. 1993 Aug 01; 82(3):737-43.
    View in: PubMed
    Score: 0.022
  32. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood. 1992 Nov 15; 80(10):2463-70.
    View in: PubMed
    Score: 0.021
  33. Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders. Blood. 1992 Mar 15; 79(6):1501-10.
    View in: PubMed
    Score: 0.020
  34. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 1990 Dec 15; 76(12):2594-8.
    View in: PubMed
    Score: 0.018
  35. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood. 2007 Sep 01; 110(5):1648-55.
    View in: PubMed
    Score: 0.014
  36. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. 1986 Jun; 67(6):1765-72.
    View in: PubMed
    Score: 0.013
  37. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986 Mar; 4(3):325-45.
    View in: PubMed
    Score: 0.013
  38. Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up. Ann Hematol. 2004 Aug; 83(8):513-21.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.